Codon Usage Optimization of HIV Type 1 Subtype Cgag,pol,env, andnefGenes:In VitroExpression and Immune Responses in DNA-Vaccinated Mice
- 1 September 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 19 (9) , 817-823
- https://doi.org/10.1089/088922203769232610
Abstract
Codon usage optimization of human immunodeficiency virus type 1 (HIV-1) structural genes has been shown to increase protein expression in vitro as well as in the context of DNA vaccines in vivo; however, all optimized genes reported thus far are derived from HIV-1 (group M) subtype B viruses. Here, we report the generation and biological characterization of codon usage-optimized gag, pol, env (gp160, gp140, gp120), and nef genes from a primary (nonrecombinant) HIV-1 subtype C isolate. After transfection into 293T cells, optimized subtype C genes expressed one to two orders of magnitude more protein (as determined by immunoblot densitometry) than the corresponding wild-type constructs. This effect was most pronounced for gp160, gp140, Gag, and Pol (>250-fold), but was also observed for gp120 and Nef (45- and 20-fold, respectively). Optimized gp160- and gp140-dervied glycoproteins were processed, incorporated into virus particles, and mediated virus entry when expressed in trans to complement an env-minus HIV-1 provirus. Mice immunized with optimized gp140 DNA developed antibody as well as CD4+ and CD8+ T cell immune responses that were orders of magnitude greater than those of mice immunized with wild-type gp140 DNA. These data confirm and extend previous studies of codon usage optimization of HIV-1 genes to the most prevalent group M subtype. Our panel of matched optimized and wild-type subtype C genes should prove valuable for studies of protein expression and function, the generation of subtype-specific immunological reagents, and the production of DNA-based sub-unit vaccines directed against a broader spectrum of viruses.Keywords
This publication has 31 references indexed in Scilit:
- Antibody neutralization and escape by HIV-1Nature, 2003
- Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic ImmunizationJournal of Virology, 2002
- Human Immunodeficiency Virus Type 1-Specific Immunity after Genetic Immunization Is Enhanced by Modification of Gag and Pol ExpressionJournal of Virology, 2001
- Elicitation of High-Frequency Cytotoxic T-Lymphocyte Responses against both Dominant and Subdominant Simian-Human Immunodeficiency Virus Epitopes by DNA Vaccination of Rhesus MonkeysJournal of Virology, 2001
- DNA Vaccination with the Human Immunodeficiency Virus Type 1 SF162ΔV2 Envelope Elicits Immune Responses That Offer Partial Protection from Simian/Human Immunodeficiency Virus Infection to CD8 + T-Cell-Depleted Rhesus MacaquesJournal of Virology, 2001
- Near Full-Length Clones and Reference Sequences for Subtype C Isolates of HIV Type 1 from Three Different ContinentsAIDS Research and Human Retroviruses, 2001
- Construction, Biological Activity, and Immunogenicity of Synthetic Envelope DNA Vaccines Based on a Primary, CCR5-Tropic, Early HIV Type 1 Isolate (BX08) with Human CodonsAIDS Research and Human Retroviruses, 2000
- Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA VaccinationScience, 2000
- Codon usage limitation in the expression of HIV-1 envelope glycoproteinCurrent Biology, 1996
- Direct Gene Transfer into Mouse Muscle in VivoScience, 1990